Federal contract award
75A50123C00045
ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | TIME AND MATERIALS |
| Obligations | $126.5M |
| Current contract value | $126.5M |
| Potential contract value / ceiling | $126.5M |
| Start date | Sep 29, 2023 |
| Current end date | Sep 28, 2029 |
| Potential end date | Sep 28, 2029 |
| Latest award activity | Aug 18, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 18, 2026 | P00006 | $0 | THE CONTRACTOR WILL FUNCTION AS THE USG'S CENTRALIZED ASSAY LABORATORY FOR IMMUNE ASSAY DEVELOPMENT AND HIGH THROUGHPUT TESTING FOR SERA AND MUCOSAL SAMPLES. |
| Mar 23, 2026 | P00005 | $0 | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI UNILATERAL MODIFICATION TO REFLECT PENDING DESCOPE AND DEOBLIGATION. |
| Jun 30, 2025 | P00004 | $0 | THE CONTRACTOR WILL FUNCTION AS THE USG'S CENTRALIZED ASSAY LABORATORY FOR IMMUNE ASSAY DEVELOPMENT AND HIGH THROUGHPUT TESTING FOR SERA AND MUCOSAL SAMPLES. |
| Dec 17, 2024 | P00003 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. UPDATE SECTION G.1 OF THE CONTRACT TO CHANGE THE CONTRACTING OFFICER TO JILL JOHNSON. TALL OTHER TERMS AND CONDITIONS REMAIN THE SAME. |
| Sep 23, 2024 | P00002 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. UPDATE SECTION G.2 OF THE CONTRACT TO CHANGE THE CONTRACTING OFFICER REPRESENTATIVE FROM MARCIELA DEGRACE TO LAKSHMI JAYASHANKAR. 2. AT NO ADDITIONAL COST TO THE GOVERNMENT UPDATE THE STATEMENT OF WORK |
| Feb 29, 2024 | P00001 | $0 | ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ |
| Sep 29, 2023 | 0 | $126.5M | ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZ |
Estimated positioning window
Sep 28, 2028 – Mar 28, 2029
45/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 45/100. Available recorded signals: 40 points.
- Contract end 2029-09-28 (1069 days from calculation)
- +15 points
- 2 historical awards in this buyer and category group
- +10 points
- 7 recorded award transactions
- +10 points
- Latest award action: 2026-08-18
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.